• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

ONE HUNDRED And Gobel Group Form Strategic Partnership in Healthcare Philanthropic Consulting

Share:

October 15, 2019

ONE HUNDRED, a multi-disciplinary agency connecting nonprofits with leading experts in brand reputation, marketing and fundraising from across Omnicom Group, has announced a strategic partnership with Gobel Group the leading philanthropy consulting firm working exclusively in healthcare and the experts in building a grateful patient and family philanthropy program with engaged clinicians.

With the significant emphasis placed on patient experience and the importance of patient satisfaction scores, a partnership between ONE HUNDRED and Gobel Group will ensure an end-to-end solution is available creating a holistic patient journey connecting different components of the hospital ecosystem – from patients, to doctors and nurses, to donors and back around again.

“We are excited by this partnership with Gobel Group,” said Brian Crimmins, Global Managing Partner of ONE HUNDRED. “Pairing the specialty and expertise of Gobel Group with the depth and breadth of experience of ONE HUNDRED, we will be the preeminent partner for leading healthcare institutions. I have been impressed by the team from Gobel Group and their track record of innovating to enhance fundraising results.”

The innovative approach that Gobel Group has in healthcare has led to tremendous growth in recent years. In addition to raising hundreds of millions of dollars in grateful patient revenue with its step-by-step process, Gobel Group has trained over 10,000 philanthropy professionals on its Top Producer gift officer program and elevated the importance of philanthropy to more than 5,000 clinicians. The program demonstrates measurable results with clients seeing a 10:1 ROI. Currently Gobel Group, with Randall Hallett as President, is actively working with more than 200 healthcare clients around the world.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Inspired by its core belief that gratitude drives the decision to give, and that wealth drives the decision of how much to give, last year Gobel Group launched a new company led by Nathan Chappell called Futurus Group that is taking G2G (“Gratitude to Give”) to market. G2G is the world’s first patient screening algorithm that uses adaptive, machine learning technology to accurately predict which patients are most likely to be grateful for their experience and therefore to donate. This process dramatically increases the efficiency and effectiveness of philanthropy programs. G2G has been proven to produce four times as many donors as wealth screening. With a specific focus on further developing existing and emerging proprietary technologies, this will continue to disrupt healthcare philanthropy by leveraging artificial intelligence and machine learning capabilities to help healthcare organizations increase philanthropic support.

“The success of our Grateful Patient Program has created opportunities to assist our clients in the areas of branding, communications and marketing and this partnership will extend the ways in which we can support our clients within our now extended family. Knowing we now have 3,200+ healthcare communications specialists in 55+ offices around the world to tap into will allow us to have a longer life cycle of servicing clients,” stated Chad Gobel, Founder & CEO of Gobel Group & Futurus Group.

Source: Nasdaq

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • Prostate Cancer Pipeline Insights: Comprehensive Analysis of Key Emerging Therapies and Pharmaceutical CompaniesProstate Cancer Pipeline Insights: Comprehensive Analysis of Key Emerging Therapies and Pharmaceutical Companies
  • Vertex to Acquire ViaCyte, with the Goal of Accelerating Its Potentially Curative VX-880 Programs in Type 1 DiabetesVertex to Acquire ViaCyte, with the Goal of Accelerating Its Potentially Curative VX-880 Programs in Type 1 Diabetes
  • The Valley of Life: A National Life Science Strategy, And The Promise of SpringThe Valley of Life: A National Life Science Strategy, And The Promise of Spring
  • How to Reduce the Attack Surface Associated with medical DevicesHow to Reduce the Attack Surface Associated with medical Devices
  • Consumer Groups, Unions Petition to Block Merger of Allergan and AbbVieConsumer Groups, Unions Petition to Block Merger of Allergan and AbbVie
  • Haystack Oncology Launches with $56M for Post-Op Cancer Detection TechHaystack Oncology Launches with $56M for Post-Op Cancer Detection Tech
  • Amazon’s One Medical acquisition passes regulatory hurdle in OregonAmazon’s One Medical acquisition passes regulatory hurdle in Oregon
  • Aduro Biotech Stockholders Approve Merger Agreement with Chinook TherapeuticsAduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications